KLDO - Kaleido BioSciences, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
18.10
+3.28 (+22.13%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close14.82
Open14.81
Bid0.00 x 800
Ask0.00 x 1000
Day's Range14.68 - 18.35
52 Week Range12.50 - 18.35
Volume83,990
Avg. Volume88,773
Market Cap536.265M
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-9.94
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est18.38
Trade prices are not sourced from all markets
  • In slow year for life science IPOs, this venture firm is making big money
    American City Business Journals12 days ago

    In slow year for life science IPOs, this venture firm is making big money

    The slowing of Massachusetts biotech and medical device companies’ stock market launches has left most venture creation firms without exit opportunities, except for one.

  • GlobeNewswire19 days ago

    Kaleido Biosciences Reports First Quarter 2019 Financial Results and Provides Corporate Update

    LEXINGTON, Mass., May 02, 2019 -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a differentiated, chemistry-driven approach to leveraging.

  • MoneyShow28 days ago

    Long-Term "GameChangers" in Biotech

    When I'm hunting for unicorns, I start with biotech. They won't all be winners. But in a well-constructed portfolio, enough of them will hit their commercial targets with sufficient force to make their shareholders very happy, explains Hilary Kramer, editor of GameChangers.

  • GlobeNewswirelast month

    Kaleido Biosciences Announces Presentation of Clinical Study and Ex Vivo Data Supporting the Development of Novel Microbiome Metabolic Therapies for Hyperammonemia at The International Liver Congress™ 2019 (EASL)

    The gut microbiome plays a significant role in the production and consumption of ammonia, which is central to the pathogenesis of several ammonia processing-related diseases. Kaleido is currently advancing novel MMT product candidates, KB195 and KB174, targeted at reducing net ammonia production by modulating the metabolic output and profile of the microbiome. “These data demonstrate the potential of our MMTs to reduce ammonia produced by the gut microbiome and support the development of lead candidates for the treatment of diseases resulting in hyperammonemia,” said Katharine Knobil, M.D., Chief Medical Officer and Head of Research & Development at Kaleido.

  • GlobeNewswirelast month

    Kaleido Biosciences Announces Key Appointments to Leadership Team

    LEXINGTON, Mass., April 08, 2019 -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a differentiated, chemistry-driven approach to leveraging.

  • GlobeNewswire2 months ago

    Kaleido Biosciences Announces Upcoming Presentations at the Society for Inherited Metabolic Disorders Annual Meeting and The International Liver Congress™ (EASL)

    Posters to feature ex vivo and in-human data supporting Kaleido’s Microbiome Metabolic Therapy programs for the treatment of hyperammonemia LEXINGTON, Mass., March 27, 2019 --.

  • GlobeNewswire2 months ago

    Kaleido Biosciences Announces Initiation of Dosing in Non-IND Clinical Studies in Patients with Urea Cycle Disorders and Cirrhosis

    Kaleido Biosciences, Inc. (KLDO), a clinical-stage healthcare company with a differentiated, chemistry-driven approach to leveraging the potential of the microbiome organ, today announced the initiation of dosing in two non-Investigational New Drug (non-IND) clinical studies evaluating KB195 in patients with urea cycle disorders (UCD) and KB174 in patients with cirrhosis.  A third non-IND clinical study evaluating various doses of KB174 in healthy subjects is also underway. The gut microbiome plays a significant role in the production and consumption of ammonia, which is central to the pathogenesis of several ammonia processing-related diseases. “As we continue to advance the development of our novel MMTs, we are pleased to have initiated dosing in these patient studies and anticipate results during the fourth quarter of 2019,” said Alison Lawton, President and Chief Executive Officer of Kaleido.

  • GlobeNewswire2 months ago

    Kaleido Biosciences to Highlight its Platform to Identify and Evaluate Microbiome Metabolic Therapies to Reduce Gut Ammonia Production in Presentation at Keystone Symposia on Microbiome

    Kaleido Biosciences, (KLDO), a clinical-stage healthcare company with a differentiated, chemistry-driven approach to leveraging the potential of the microbiome organ to treat disease and improve human health, today announced that a scientific poster and presentation describing its proprietary product platform and the identification of its lead product candidate, KB195, will be featured during the Keystone Symposia meeting, Microbiome: Chemical Mechanisms and Biological Consequences, which will be held from March 10-14, 2019, in Montreal, Québec. The poster entitled, “Developing a Drug Discovery Platform to Target Gut Microbiota-Associated Ammonia Production,” will be displayed during Poster Session 2 from 7:30-10:00 pm ET on Tuesday, March 12, 2019.

  • GlobeNewswire3 months ago

    Kaleido Biosciences Announces Closing of Initial Public Offering

    Kaleido Biosciences, Inc. (KLDO), a clinical-stage healthcare company with a differentiated, chemistry-driven approach to leveraging the potential of the microbiome organ to treat disease and improve human health, today announced the closing of its initial public offering of 5,000,000 shares of common stock at a public offering price of $15.00 per share. All of the shares in the offering were offered by Kaleido. Goldman Sachs, J.P. Morgan and Morgan Stanley acted as joint book-running managers for the offering. Canaccord Genuity acted as lead manager for the offering.

  • GlobeNewswire3 months ago

    Nasdaq Welcomes Kaleido Biosciences, Inc. (Nasdaq: KLDO) to the Nasdaq Stock Market

    Kaleido Biosciences, Inc. (KLDO), a clinical-stage healthcare company with a differentiated, chemistry-driven approach focused on leveraging the potential of the microbiome organ to treat disease and improve human health, rang the Nasdaq MarketSite bell in Times Square today in celebration of its initial public offering (IPO) on The Nasdaq Stock Market. Kaleido has built a human-centric proprietary product platform to enable the rapid and cost-efficient discovery and development of novel Microbiome Metabolic Therapies (MMT™).  The Company is advancing a broad pipeline of MMT candidates with the potential to address a variety of diseases and conditions with significant unmet patient needs. “We are excited to join Nasdaq as we continue to work to translate the promise of the microbiome into solutions for patients,” said Alison Lawton, President and Chief Executive Officer, Kaleido.

  • GlobeNewswire3 months ago

    Kaleido Biosciences Announces Pricing of Initial Public Offering

    Kaleido Biosciences, Inc. (KLDO), a clinical-stage healthcare company with a differentiated, chemistry-driven approach to leveraging the potential of the microbiome organ to treat disease and improve human health, today announced the pricing of its initial public offering of 5,000,000 shares of common stock at a public offering price of $15.00 per share, before underwriting discounts and commissions. In addition, Kaleido has granted the underwriters a 30-day option to purchase up to an additional 750,000 shares of common stock at the initial public offering price, less the underwriting discounts and commissions. Kaleido’s common stock is expected to begin trading on The Nasdaq Global Select Market on February 28, 2019, under the ticker symbol “KLDO.” All of the common stock in the offering is being offered by Kaleido.

  • Benzinga3 months ago

    IPO Outlook For The Week: Gaming And Biotech

    For a more comprehensive IPO calendar, check out the offering in Benzinga Cloud . IPO dates below are expected but not confirmed. Super League Gaming, Inc. (SLGG) will issue nearly 2.3 million shares between ...